Wintermute is Now Recruiting Patients for the ZosterEase Phase Ib Clinical Trial. Read more .

As a research-led healthcare company, we strive to develop solutions and medicines where there is high unmet need.

Our Technology: Harnessing the Power of Fatty Acids

Fatty acids have strong antibacterial, antifungal, and antiviral activity. But their solubility in water poses a challenge to using them in a clinical setting. We have developed a powerful, next-generation, and safe solution to this; by using amino acids, part of everyday foods, we have developed a method to get the fatty acids to solubilize in water. We are leveraging this patented platform to let the fatty acids shine. This platform opens the door to a multitude of applications in healthcare, agriculture, and more.

For over 10 years we have been refining and testing several formulations with more than 10 different fatty acids. Each has its own unique applications. The advantages of using fatty acids as therapeutics include:


High levels of potency in treating infectious organisms.

Excellent safety

Water solubility means nasty solvents aren't required. And since fatty acids naturally occur in our diet, they are well tolerated. Can be applied topically.

Broad spectrum

Activity against gram-positive and gram-negative bacteria, fungi and viruses.

Combats resistance

No evidence of resistance development during standardized testing (GS-1).

Long lasting

Our formulation remains active, conferring ongoing protection against infections.

Environmentally Friendly

No harmful chemicals, water-based, and naturally occurring active ingredients.


Wintermute compounds have demonstrated efficacy for a wide range of organisms; most of which make up the CDC’s Biggest Threats list

Infectious Organisms

  • Carbapenem-resistant Enterobacteriaceae (CRE)
  • ‍Extended spectrum beta-lactamase producing Enterobacteriaceae (ESBLs)
  • ‍Multidrug-resistant Pseudomonas aeruginosa
  • ‍Methicillin-resistant Staphylococcus aureus (MRSA)
  • ‍Drug-resistant Streptococcus pneumoniae
  • ‍Vancomycin-resistant Staphylococcus aureus (VRSA)
  • ‍Drug-resistant Streptococcus (Groups A and B)
  • ‍MCR-1 (E. coli)
  • Mycobacterium ulcerans
  • Many more

Therapeutic applications

At Wintermute Biomedical, we are performing leading-edge research on next-generation therapeutics and consumer products to prevent and combat infectious diseases. We are actively researching, developing, and testing:

Our lead therapy, Solexan, as a topical treatment for shingles, caused by Varicella Zoster virus.

New formulations to treat methicillin-resistant Staphylococcus aureus that causes Impetigo.

New formulations to treat Buruli ulcers, caused by Mycobacterium ulcerans.